Cannovum Health welcomes new strategic majority investor
Advertisement
Cannovum Health GmbH celebrates a key milestone in its corporate development: Triple Crown Ventures becomes the new majority investor. With this step, the company gains a financially strong and strategic partner who firmly believes in Cannovum Health’s vision. In addition to increasing Cannovum Health’s capital, Triple Crown Ventures acquired shares from the founders and other shareholders to obtain a majority stake.
As a specialized investment firm focused on acquisitions and investments across the entire medical cannabis value chain, Triple Crown Ventures will actively support Cannovum Health in its continued expansion.
Pia Marten, co-founder and long-standing CEO of Cannovum Health, will continue as CEO and shareholder. Co-founder Marius Koose and Head of Sales Dr. Paul Weber will maintain their strategic and operational responsibilities and continue as shareholders. The existing team will be retained in full, with further hires planned to drive targeted growth.
“With Triple Crown Ventures as our partner, we are ready to enter the next growth phase – with a clear goal of developing Cannovum Health into a leading player in the German medical cannabis market,” says Pia Marten, Co-Founder and CEO.
Cannovum Health eG was founded in 2019 together with its then parent company Cannovum Cannabis AG by Pia Marten and Marius Koose. In June 2023, Pia Marten, Marius Koose, and Dr. Paul Weber completed a management buy-out of Cannovum Health, acquiring the entire medical cannabis business from the AG. Since then, there have been no operational ties to Cannovum Cannabis AG. As part of the Triple Crown Ventures investment, the AG has now also sold its remaining minority stake. In the course of the transaction, Cannovum Health eG was converted into a GmbH. The transaction was successfully facilitated by Hyde Advisory & Investments Inc.
“The acquisition by Triple Crown Ventures has made our management buy-out a complete success. Together with our team, we have built a strong foundation over the past two years – now we can build on it with a strong partner,” says Marius Koose, Co-Founder of Cannovum Health.
Cannovum Health GmbH is consistently focused on growth – with a clear emphasis on high quality own brands, reliable pharmacy distribution, and modern sales channels.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Dr. Wolf-Henning Walther becomes new CEO at Metrohm Germany - Change in the Executive Board from September 1, 2025
Norgine completes acquisition of Theravia
New method loads mRNA into exosomes in 10 minutes—just mix and go - KIST team develops cubosome-based method for loading large therapeutics without damaging exosomes
Reduced genome – flexible performance: How symbiotic bacteria with minimal genetic information support their host - Despite having only a tiny genome, the symbionts of reed beetles can adapt their gene activity flexibly to the developmental stages and ambient temperatures of their hosts
Insights into olfactory disorders in Alzheimer's disease
Ultrasound could deliver drugs with fewer side effects
Using bacteria to sneak viruses into tumors - The bioengineered platform enables a cancer-killing virus to evade the patient’s immune system — and prevents it from spreading throughout the body.
The diamonds that could find cancer - Endoscopic diamond magnetometer for cancer surgery
Stora Enso’s billion-euro investment in renewable packaging - Europe's most modern consumer board production line inaugurated in Finland
Sensing sour: How SNAP25 powers taste signals and keeps sensory cells alive - SNAP25 enables sour taste perception by supporting both signal transmission and the long-term survival of type III taste cells
